Federal Science and Technology Grants

Scientific observations, experiments, and simulations are producing data at rates beyond our capacity to store, analyze, stream, and archive the data in raw form. Of necessity, many research groups have already begun reducing the size of their data sets via techniques such as compression, reduced order models, experiment-specific triggers, filtering, and feature extraction. Once reduced in size, transporting, storing, and analyzing the data is still a considerable challenge a reality that motivates SCs Integrated Research Infrastructure (IRI) program [1] and necessitates further innovation in data-reduction methods. These further efforts should continue to increase the level of mathematical rigor in scientific data reduction to ensure that scientifically-relevant constraints on quantities of interest are satisfied, that methods can be integrated into scientific workflows, and that methods are implemented in a manner that inspires trust that the desired information is preserved. Moreover, as the scientific community continues to drive innovation in artificial intelligence (AI), important opportunities to apply AI methods to the challenges of scientific data reduction and apply data-reduction techniques to enable scientific AI, continue to present themselves [2-4].The drivers for data reduction techniques constitute a broad and diverse set of scientific disciplines that cover every aspect of the DOE scientific mission. An incomplete list includes light sources, accelerators, radio astronomy, cosmology, fusion, climate, materials, combustion, the power grid, and genomics, all of which have either observatories, experimental facilities, or simulation needs that produce unwieldy amounts of raw data. ASCR is interested in algorithms, techniques, and workflows that can reduce the volume of such data, and that have the potential to be broadly applied to more than one application. Applicants who submit a pre-application that focuses on a single science application may be discouraged from submitting a full proposal.Accordingly, a virtual DOE workshop entitled Data Reduction for Science was held in January of 2021, resulting in a brochure [5] detailing four priority research directions (PRDs) identified during the workshop. These PRDs are (1) effective algorithms and tools that can be trusted by scientists for accuracy and efficiency, (2) progressive reduction algorithms that enable data to be prioritized for efficient streaming, (3) algorithms which can preserve information in features and quantities of interest with quantified uncertainty, and (4) mapping techniques to new architectures and use cases. For additional background, see [6-9].The principal focus of this FOA is to support applied mathematics and computer science approaches that address one or more of the identified PRDs. Research proposed may involve methods primarily applicable to high-performance computing, to scientific edge computing, or anywhere scientific data must be collected or processed. Significant innovations will be required in the development of effective paradigms and approaches for realizing the full potential of data reduction for science. Proposed research should not focus only on particular data sets from specific applications, but rather on creating the body of knowledge and understanding that will inform future scientific advances. Consequently, the funding from this FOA is not intended to incrementally extend current research in the area of the proposed project. Rather, the proposed projects must reflect viable strategies toward the potential solution of challenging problems in data reduction for science. It is expected that the proposed projects will significantly benefit from the exploration of innovative ideas or from the development of unconventional approaches. Proposed approaches may include innovative research with one or more key characteristics, such as compression, reduced order models, experiment-specific triggers, filtering, and feature extraction, and may focus on cross-cutting concepts such as artificial intelligence or trust. Preference may be given to pre-applications that include reduction estimates for at least two science applications.

This grant provides funding for innovative researchers to explore groundbreaking ideas and methods in glioblastoma research, particularly encouraging early-career scientists and collaborations with experienced experts.

This solicitation describes an ambitious program to fund international, interdisciplinary collaborative research centers that will apply best practices of broadening participation and community engagement to develop use-inspired bioeconomy research to address one or more global challenges identified by the scientific community. Here, the "used-inspired" nature of the research refers to project outcomes leading to foreseeable benefits to society. This program will prioritize research collaborations that foster team science and community-engaged research, use knowledge-to-action frameworkswhose rationale, conceptualization, and research directions are driven by the potential use of the results as illustrated by Pasteurs Quadrant (see Stokes, Donald E. (1997), "Pasteur;apos;s Quadrant - Basic Science and Technological Innovation," Brooking Institution Press, p.196. ISBN 9780815781776).Proposals should also indicate how research will be co-generated with communities and stakeholders identified in the proposal. The proposed research should maximize the benefits of international, interdisciplinary collaborations, and describe the roles and responsibilities of each national team in achieving the goals of the proposed Global Center. Global Centers projects involving partnership between the U.S. and two or more partner countries are strongly encouraged. Global challenges must be addressed through international collaboration and researchers are encouraged to develop international teams to address research questions that can only be addressed through multilateral efforts. The topic for the 2024 competition of the Global Centers program is Addressing Global Challenges through the Bioeconomy and may include research from any combination of research disciplines supported by NSF. The Bioeconomy is the share of the economy based on products, services, and processes derived from living systems.Research investments to advance the bioeconomy serve to accelerate scientificdiscovery and to enable the harnessing, engineering, and rational modulation ofbiological systemsto create goods and services that contribute to the agriculture,health, security, manufacturing, energy, and environmental sectors of the global economy; or that provide access to unique systems that help us understand the processes and issues that we can use biotechnology to solve. Bioeconomy is built on the foundation of biotechnology and biomanufacturing, and in addition to biological science and engineering includes contributions from fields such as chemistry, materials science, geosciences, mathematics, data sciences, humanities, and the social sciences. The world is facing many serious challenges, including, but not limited to, adapting to or mitigating the effect of climate change, developing clean energy approaches, identifying and advancing sustainable food systems, addressing water insecurity, exploring solutions to emerging infectious diseases, creating resource efficiency, sustaining biodiversity, addressing inequalities in access to biotechnologies, and developing a circular bioeconomy. For example, bio-based materials offer heightened biodegradability and biosafety as compared to reusable plastic materials that shed microplastics during use and washing and affect water security and human health. This Global Centers solicitation in Bioeconomy offers a unique opportunity for interdisciplinary teams of scientists, educators, and practitioners to use knowledge of the bioeconomy to co-develop and execute a research plan for an international center that will address a global challenge facing humanity. The Global Centers program is meant to support multidisciplinary research that can only be achieved through international partnerships uniting complementary areas of expertise, and/or facilitating access to unique expertise or resources of the participating countries. The proposal should explain how the center will maximize the benefits of international collaborations and describe the unique contributions and the roles and responsibilities of each national team in achieving the goals of the proposed Global Center. Successful proposals will describe how the center will tackle a global challenge that can only be addressed through the diversity of knowledge, skills, and resources united in this center. Addressing global challenges requires international engagement and must go beyond production of data to demonstrate how co-generation and co-production of research with stakeholder groups can maximize the chances of research outcomes being taken up by target groups and applied to address the global challenge. Because change requires human involvement, this process, described as the Knowledge to Action framework explicitly recognizes the need to involve appropriate scientific experts and practitioners who study and work with humans in implementing the human action aspect of the framework. Examples of human action include (but are not limited to) studies in human and societal behavior, in policy, economics, psychology, anthropology, or education. Proposals are expected to describe a center that fully integrates human action elements with the knowledge generation portions of the center to produce a holistic, multi-disciplinary center that is greater than the sum of its parts. The center should offer a plan of research in which disciplines are integrated and complement and support each other to produce world class research, train the next generation of workforce, and use best practices to ensure that participant communities and stakeholder groups are involved in all stages of the research process so that outcomes are aligned with their needs and readily adoptable. Within the general theme of Bioeconomy, proposals submitted in the framework of this call must be centered on either or both of the two subtopics: Subtopic 1:Leveraging Biodiversity Across the Tree of Life to Power the Bioeconomy; and Subtopic 2: Biofoundries, using the Design-Build-Test-Learn process in biology. All proposals must integrate both of the two crosscutting themes into the proposed work: Crosscutting Theme A: Public engagement and co-generation of research activities to strengthen the global science and technology enterprise; andCrosscutting Theme B: Workforce Development and Education. See Section II, Program Description for details.

With this solicitation, NIJ seeks to support two (2) American Association for the Advancement of Science (AAAS) Science Technology Policy Fellowships (STPF) Fellows at NIJ. The AAAS STPF Fellow, as mutually agreed, will be assigned responsibilities across NIJs science offices depending on the interests of the science offices and the interests of the Fellows. Regardless of placement, the Fellows will have the opportunity to work across offices. The Fellows will have opportunities to engage in a range of science (including social and behavioral science), technology, engineering, and mathematics research development and evaluation projects.

This funding opportunity provides financial support for researchers and organizations focused on advancing the understanding and management of water resources through innovative applications in space and Earth sciences.

This grant provides funding for U.S. institutions to conduct innovative research using existing lunar data, enhancing our understanding of the Moon's geology, environment, and its role in space exploration.

This funding opportunity is designed for research institutions affiliated with the Southern Appalachian Mountains CESU to study climate adaptation in oak-dominated ecosystems and their impact on wildlife, with a focus on species distribution and resource management.

The OCRP Pilot Award supports the exploration of innovative concepts or theories in ovarian cancer that could ultimately lead to critical discoveries or major advancements that will drive the field forward. The proposed research must demonstrate a clear focus on ovarian cancer (e.g., using tissues, cell lines, datasets, or appropriate animal models), and serve as a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer. If cell lines or animals are to be used, a clear justification should be provided for the choice of proposed cell line(s) or animal model(s).

To obtain a copy of the Funding Opportunity Announcement (FOA) please go to the ARPA-E website at https://arpa-e-foa.energy.gov. To apply to this FOA, Applicants must register with and submit application materials through ARPA-E eXCHANGE (https://arpa-e-foa.energy.gov/Registration.aspx). For detailed guidance on using ARPA-E eXCHANGE, please refer to the ARPA-E eXCHANGE User Guide (https://arpa-e-foa.energy.gov/Manuals.aspx). ARPA-E will not review or consider concept papers submitted through other means. For problems with ARPA-E eXCHANGE, email ExchangeHelp@hq.doe.gov (with FOA name and number in the subject line). Questions about this FOA? Check the Frequently Asked Questions available at http://arpa-e.energy.gov/faq. For questions that have not already been answered, email ARPA-E-CO@hq.doe.gov. Agency Overview: The Advanced Research Projects Agency Energy (ARPA-E), an organization within the Department of Energy (DOE), is chartered by Congress in the America COMPETES Act of 2007 (P.L. 110-69), as amended by the America COMPETES Reauthorization Act of 2010 (P.L. 111-358), as further amended by the Energy Act of 2020 (P.L. 116-260): (A) to enhance the economic and energy security of the United States through the development of energy technologies that (i) reduce imports of energy from foreign sources; (ii) reduce energy-related emissions, including greenhouse gases; (iii) improve the energy efficiency of all economic sectors; (iv) provide transformative solutions to improve the management, clean-up, and disposal of radioactive waste and spent nuclear fuel; and (v) improve the resilience, reliability, and security of infrastructure to produce, deliver, and store energy; and (B) to ensure that the United States maintains a technological lead in developing and deploying advanced energy technologies. ARPA-E issues this Funding Opportunity Announcement (FOA) under its authorizing statute codified at 42 U.S.C. 16538. The FOA and any cooperative agreements or grants made under this FOA are subject to 2 C.F.R. Part 200 as supplemented by 2 C.F.R. Part 910. ARPA-E funds research on, and the development of, transformative science and technology solutions to address the energy and environmental missions of the Department. The agency focuses on technologies that can be meaningfully advanced with a modest investment over a defined period of time in order to catalyze the translation from scientific discovery to early-stage technology. For the latest news and information about ARPA-E, its programs and the research projects currently supported, see: http://arpa-e.energy.gov/. ARPA-E funds transformational research. Existing energy technologies generally progress on established learning curves where refinements to a technology and the economies of scale that accrue as manufacturing and distribution develop drive improvements to the cost/performance metric in a gradual fashion. This continual improvement of a technology is important to its increased commercial deployment and is appropriately the focus of the private sector or the applied technology offices within DOE. In contrast, ARPA-E supports transformative research that has the potential to create fundamentally new learning curves. ARPA-E technology projects typically start with cost/performance estimates well above the level of an incumbent technology. Given the high risk inherent in these projects, many will fail to progress, but some may succeed in generating a new learning curve with a projected cost/performance metric that is significantly better than that of the incumbent technology. ARPA-E funds technology with the potential to be disruptive in the marketplace. The mere creation of a new learning curve does not ensure market penetration. Rather, the ultimate value of a technology is determined by the marketplace, and impactful technologies ultimately become disruptive that is, they are widely adopted and displace existing technologies from the marketplace or create entirely new markets. ARPA-E understands that definitive proof of market disruption takes time, particularly for energy technologies. Therefore, ARPA-E funds the development of technologies that, if technically successful, have clear disruptive potential, e.g., by demonstrating capability for manufacturing at competitive cost and deployment at scale. ARPA-E funds applied research and development. The Office of Management and Budget defines applied research as an original investigation undertaken in order to acquire new knowledgedirected primarily towards a specific practical aim or objective and defines experimental development as creative and systematic work, drawing on knowledge gained from research and practical experience, which is directed at producing new products or processes or improving existing products or processes. Applicants interested in receiving financial assistance for basic research (defined by the Office of Management and Budget as experimental or theoretical work undertaken primarily to acquire new knowledge of the underlying foundations of phenomena and observable facts) should contact the DOEs Office of Science (http://science.energy.gov/). Office of Science national scientific user facilities (http://science.energy.gov/user-facilities/) are open to all researchers, including ARPA-E Applicants and awardees. These facilities provide advanced tools of modern science including accelerators, colliders, supercomputers, light sources and neutron sources, as well as facilities for studying the nanoworld, the environment, and the atmosphere. Projects focused on early-stage R for the improvement of technology along defined roadmaps may be more appropriate for support through the DOE applied energy offices including: the Office of Energy Efficiency and Renewable Energy (http://www.eere.energy.gov/), the Office of Fossil Energy and Carbon Management (https://www.energy.gov/fecm/office-fossil-energy-and-carbon-management), the Office of Nuclear Energy (http://www.energy.gov/ne/office-nuclear-energy), and the Office of Electricity (https://www.energy.gov/oe/office-electricity). Program Overview: The energy transition towards net-zero by 2050 demands an unprecedented level of innovation that must be completed in the span of a generation. Global primary energy usage has increased continuously for the past century. This increase is expected to continue with improved standards of living and the rapid expansion of new technologies with high levels of energy-intensive computation, such as artificial intelligence. Present grid capacity is constrained and cannot accommodate these increasing primary energy needs to reliably deliver power on demand. Meanwhile, all paths through the energy transition require concurrent efforts to decouple the production of essential carbon-based materials from harmful greenhouse gas (GHG) emissions. Since the Agencys inception, the ARPA-E OPEN program has served as an opportunity to advance transformative energy breakthroughs in critical areas that fall outside the scope of its technology-focused programs. Vision OPEN challenges the research community to develop groundbreaking technologies to enable a future energy landscape that is dramatically different. The Vision includes three goals that are critical to achieve a sustainable energy and carbon transition with: 1) GHG-free abundant primary energy; 2) An intermodal energy superhighway that transports diversified forms of primary energy; and 3) A carbon transition that sustainably meets demand for polymers and other materials. To view the FOA in its entirety, please visit https://arpa-e-foa.energy.gov.

The OCRP Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ovarian cancer. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials through large-scale trials to determine efficacy in relevant patient populations.

The CTRA supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including diagnosis, prognosis, or treatment of TSC. Projects supported by this award mechanism may include, but are not limited to: Studies moving from preclinical to clinical research and/or the reverse; or analyzing human anatomical substances and/or data associated with completed clinical trials to understand the mechanism of action, or to improve diagnosis, prognosis, or treatment. Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of pharmacokinetics/pharmacodynamics. Pilot clinical trials, where limited clinical testing (e.g., small sample size) of a novel intervention to produce information on diagnostic or therapeutic effectiveness, safety, tolerability, or mechanisms of action. These studies should be aimed at obtaining preliminary data leading to the development of interventions with the potential to improve TSC outcomes. New Studies improving clinical care of TSC encompassing the analysis of existing real-world clinical practice data to develop/improve guidelines for better outcomes in defined areas relevant to the FY24 TSCRP focus areas, include but are not limited to epilepsy surgery, tumor resection, reproductive health, perinatal surveillance and care, etc.Preclinical studies may be appropriate but must include a clinical component. Projects that are strictly animal research will not be considered for CTRA funding and should consider other FY24 TSCRP funding opportunities.

This grant provides funding for innovative research projects focused on understanding and treating rare cancers, targeting researchers and institutions dedicated to advancing medical knowledge in this area.

This funding opportunity supports innovative research teams in the U.S. that are developing advanced data science and artificial intelligence solutions to improve healthcare monitoring, diagnosis, and intervention.

The FY24 ALSRP Pilot Clinical Trial Award supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of ALS. Projects may range from phase 1 to small-scale phase 2 trials and should aim to de-risk and inform the design of more advanced trials by investigating safety, feasibility, biomarker application, and therapeutic efficacy in relevant patient populations. Clinical trials may be designed to evaluate promising drugs, biologics, or devices with anticipated therapeutic impact that is supported by strong scientific rationale and existing preliminary studies and/or preclinical data. Clinical trials aimed to improve aspects of patient care and ALS symptom management are also applicable to this award mechanism.Funding from this award mechanism must support a clinical trial. A clinical trial is defined as a research study in which one or more study participants are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other FY24 ALSRP program announcements being offered. Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. Applicants must clearly describe a biomarker-driven approach and its potential to de-risk and improve the design of anticipated later-stage trials. For further description, see Attachment 13, Biomarker Statement. Biomarker development and characterization can include target engagement biomarkers, pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic, and/or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual patient or patient subgroup.Key aspects of the FY24 ALSRP Pilot Clinical Trial Award mechanism include:Impact: Potential impact from a pilot clinical trial is not whether an intervention is ready at the conclusion of the trial, but rather if the outcomes will improve and accelerate future larger trials or clinical care and symptom management. Applications submitted to this award can have outcomes that focus on specific subpopulations of ALS patients or potentially even individual patients.Biomarker-Driven Interventions: Therapeutic outcomes should directly and substantially de-risk and inform the design of anticipated later-phase trials of the intervention under investigation.Clinical Care: Improving aspects of clinical care and symptom management should have near-term impact on patients. All interventions must offer significant potential impact for individuals affected by ALS; however, this may include just specific subpopulations or potentially even individual patients.Employing Community Collaborations to Optimize Research Impact Is Required. Research funded by the FY24 ALSRP Pilot Clinical Trial Award should be responsive to the needs of people with ALS, their families, and/or their care partners. Research teams are therefore required to establish and utilize effective and equitable collaborations and partnerships with Community members to maximize impact potential of the proposed research. These collaborations are expected to facilitate accessible, efficient, and humane clinical trials. Applications to the FY24 ALSRP Pilot Clinical Trial Award must name at least one Community partner (e.g., person with ALS, family member and/or caregiver, representative of a community-based organization) who will provide advice and consultation throughout the planning and implementation of the research project. Scientific researchers and Community members will collaborate and contribute equitably on all aspects of the project, which may include needs assessment, planning, research intervention design, implementation, evaluation, and dissemination. Interactions with other team members should be well integrated and ongoing, not limited to attending seminars and semi-annual meetings. Examples for implementing collaborative research approaches include:Person Living with ALS, Family Member, and/or Caregiver: The research team includes a person with ALS, their family member, or caregiver (past or present) as a project advisor who will provide advice and consultation throughout the planning and implementation of the research project.Partnership with a Community-Based Organization: The research team establishes partnerships with at least one Community-based organization that provides advice and consultation throughout the planning and implementation of the research project. Community-based organizations may include advocacy groups, service providers, policymakers, or other formal organizational stakeholders.Community Advisory Board: A Community advisory board is composed of multiple Community stakeholders and can take many forms, from a board of people with ALS, their family members, or caregivers to a coalition of Community-based organizations or any combination thereof. As with people living with ALS and organizational partners, the Community advisory board provides advice and consultation throughout planning and implementation of the research project.Clinical Trial Start Date and Intervention Availability: The proposed clinical trial is expected to begin no later than 12 months after the award date or 18 months after the award date for Food and Drug Administration (FDA)-regulated studies. The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study.Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study.Research Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of FDA processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local Institutional Review Board (IRB) of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312), Subpart D, are fulfilled.Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projection that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If FDA-regulated, the trial must use a 21 CFR 11-compliant database and appropriate data standards. For more on data standards, see https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/ FormsSubmissionRequirements/ElectronicSubmissions/UCM511237.pdf.Transition Plan: Applications should include a transition plan (including potential funding and resources) showing how the intervention will progress to the next clinical trial phase and/or improve current standards of care after the successful completion of the FY24 ALSRP Pilot Clinical Trial Award.Milestone meeting: The Principal Investigator (PI) will be required to present an update on progress toward accomplishing the goals of the award at annual, virtual In Progress Review meetings to be held during the period of performance. The PI should ideally include their Community collaboration partner(s) in the meeting. The In Progress Review Meeting will be attended by members of the ALSRP Programmatic Panel, CDMRP staff, the USAMRAA Grants/Contracts Officer, and other stakeholders.

Regional Scale Collaboration to Facilitate a Domestic Critical Minerals Future: Carbon Ore, Rare Earth, and Critical Minerals (CORE-CM) Initiative The planned Research and Development will provide a regional scale understanding of critical minerals prospectivity and provides insight into the potential materials that may be sourced from domestic secondary and unconventional feedstocks across the United States. The work will contribute to the development of a framework that addresses economic and supply chain barriers, leads to pilot scale demos, and broaden scope to include advanced carbon or critical mineral bearing material products.

The National Science Foundation (NSF) seeks to increase the scale and pace of advancing discoveries made while conducting academic research into tangible solutions that benefit the public. This is the primary aim of the Accelerating Research Translation (ART) program. Specifically, the primary goals of this program are to build capacity and infrastructure for translational research at U.S. Institutions of Higher Education (IHEs) and to enhance their role in regional innovation ecosystems. In addition, this program seeks to effectively train graduate students and postdoctoral researchers in translational research, benefiting them across a range of career options. A particular intent of ART is to support IHEs that want to build the necessary infrastructure to boost the overall institutional capacity to accelerate the pace and scale of translation of fundamental research outcomes into practice by supporting the development of a range of activities essential for this activity. The ART program is not intended to support IHEs that already have high levels of translational research activity as part of their R enterprise (as noted by their number of invention disclosures, patents issued, start-ups, licenses/options, revenue from royalties, the overall volume of industry-funded research, broad adoption of research outputs by communities or constituents, etc.). Such institutions are encouraged to become part of the ART network as valuable collaborators, providing expertise in building the necessary infrastructure for translational research at other IHEs responding to this solicitation. The ART program is also not intended as a resource for conducting additional fundamental research. See sections II and VI of this solicitation for additional information. This solicitation seeks proposals that enable IHE-based teams to propose a blend of: (1) activities that will help build and/or strengthen the institutional infrastructure to sustainably grow the institutional capacity for research translation in the short and long terms; (2) educational/training opportunities, especially for graduate students and postdoctoral researchers, to become entrepreneurs and/or seek use-inspired and/or translational research-oriented careers in the public and/or private sectors; and (3) specific, translational research activities that offer immediate opportunities for transition to practice to create economic and/or societal impact. The funded teams will form a nationwide network of ART Ambassadors who will champion the cause of translational research.

This funding opportunity provides financial support for U.S. researchers to conduct rapid-response investigations and innovative studies in Earth Science, addressing urgent scientific questions and environmental events.

This funding opportunity provides financial support to non-profit organizations, educational institutions, and individuals from the U.S. and Kyrgyz Republic to enhance STEM education and resources in Kyrgyzstan, addressing barriers to innovation and economic growth.

The USGS is offering a funding opportunity to a CESU partner for research in evaluating the efficacy of Incompatible Insect Technique (IIT) as a mosquito population suppression control strategy designed to disrupt the avian malaria disease cycle. The CESU partner will develop statistical models that incorporate capture rates of Southern house mosquitoes (Culex quinquefasciatus) and the prevalence of Plasmodium relictum in mosquito samples to characterize the efficacy of the IIT project and disease pressure on Hawaiian forest birds in critical forest bird habitat. Another component of this research will be to develop a high-throughput, next-generation sequencing technique to quantify the prevalence of avian malaria and test whether that approach is comparable to quantitative PCR-based avian malaria assays.

This program provides funding to enhance workforce development by offering hands-on learning opportunities in emerging technology fields for individuals from diverse and historically underrepresented backgrounds.